Modern possibilities to prevent antibiotic resistance: bacteriophages as antimicrobial agents
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Альтернативний засіб санації резидентних носіїв золотистого стафілокока / Коцар О.В., Кочнєва О.В., Долгова Т.С., Малюченко А.Ю. // Інфекційні хвороби. – 2016. – Т. 2. – С. 54–57.
Бабалова Г.Г. О профилактическом значении дизентерийного сухого бактериофага / Г.Г. Бабалова, К.Т. Кацитадзе, Л.А. Сакварелидзе // Журн. микробиол. – 1968. – No 2. – C. 143–145.
Глобальный план действий по борьбе с устойчивостью к противомикробным препаратам [Електронний ресурс]: Всемирная организация здравоохранения, 2016 г. Режим доступу: http://apps.who.int/iris/bitstream/10665/254884/1/9789244509760-rus.pdf?ua=1
Жмінько П.Г. Бактеріофаги: актуальні питання безпечного застосування (огляд літератури) / П.Г. Жмінько, О.В. Федченко, М.Л. Зінов’єва // Сучасні проблеми токсикології, харчової та хімічної безпеки. – 2015. – No 3. – С. 71–81.
A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibioticresistant Pseudomonas aeruginosa; a preliminary report of efficacy / A. Wright, C.H. Hawkins, E.E. Anggеrd, D.R. Harper // Clin Otolaryngol. – 2009. – Vol. 34. – P. 349–357.
Abedon S.T. Phages, Ecology, Evolution / S.T. Abedon // In: Bacteriophage Ecology: Population Growth, Evolution, and Impact of Bacterial Viruses. Ed.: Abedon S.T. – Cambridge University Press, 2008. – P. 1–28.
Alternatives to antibiotics – a pipeline portfolio review / L. Czaplewski, R. Bax, M. Clokie, et al. // Lancet Infect Dis. – 2016. – Vol. 16, N 2. – P. 239–251.
Antibacterial and biofilm removal activity of a podoviridae Staphylococcus aureus bacteriophage SAP-2 and a derived recombinant cell-wall-degrading enzyme / J.S. Son, S.J. Lee, S.Y. Jun, et al.// Appl Microbiol Biotechnol. – 2010. – Vol. 86. – P. 1439–1449.
Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell / D.V. Rakhuba, E.I. Kolomiets, E.S. Dey, G.I. Novik // Pol. J. Microbiol. – 2010. – Vol. 59, N 3. – P. 145–155.
Bacteriophage therapy in children: Facts and prospects / W. Fortuna, R. Miedzybrodzki, B. Weber DNobrowska, A. Górski // Med Sci Monit. – 2008. – Vol. 14, N 8. – P. 126–132.
Bacteriophage therapy – Looking back in to the future / S.R. Patel, A.K. Verma, V.C. Verma et al. // In: The Battle Against Microbial Pathogens: Basic Science, Technological Advances and Educational Programs. Ed.: A. Méndez Vilas. – Badajoz (Spain): Formatex Microbiology Series N 5, 2015. – Vol. 1. – P. 284–294.
Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial / D.D. Rhoads, R.D. Wolcott, M.A. Kuskowski, et al. // J Wound Care. – 2009. – Vol. 18. – P. 237–238.
Bacteriophages and its applications: an overview / S. Sharma, S. Chatterjee, Sю Datta, et al. // Folia Microbiol (Praha). – 2017. – Vol. 62, N 1. – P. 17–55.
Characterization of a new metallo-β-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India / D. Yong, M.A. Toleman, C.G. Giske, et al. // Antimicrob Agents Chemother. – 2009. – Vol. 53, N 12. – P. 5046–5054.
Comprehensive resistome analysis reveals the prevalence of NDM and MCR-1 in Chinese poultry production / Y. Wang, R. Zhang, J. Li et al. // Nature Microbiology. – 2017. – N 2. – pii.16260.
Emergence of plasmid mediated colistin resistance mechanism mcr-1 in animals and human beings in China: a microbiological and molecular biological study / Y.Y. Liu, Y. Wang, T.R. Walsh, et al. // Lancet Infect Dis. – 2016. – Vol. 16, N 2. – P. 161–168.
Escherichia coli harboring mcr-1 and blaCTX M on a novel IncF plasmid: First report of 2 mcr-1 in the USA / P. McGann, E. Snesrud, R. Maybank, et al. // Antimicrob. Agents Chemother. – 2016. – Vol. 60, N 7. – P. 4420–4421.
Experimental phage therapy of burn wound infection: difficult first steps / T. Rose, G. Verbeken, D. De Vos, et al. // Int. J. Burn Trauma. – 2014. – Vol. 4, N 2. – P. 66–73.
Hall B.G. Independent origins of subgroup Bl + B2 and subgroup B3 metallo-β-lactamases / B.G. Hall, S.J. Salipante, M. Barlow // J MolEvol. – 2004. – Vol. 59, N 1. – P. 133–141.
Hyman P. Bacteriophage host range and bacterial resistance / P. Hyman, ST Abedon // Adv. Appl. Microbiol. – 2010. – Vol. 70. – P. 217–248.
IMP Producing Carbapenem Resistant Klebsiella pneumoniae in the United States / B.M. Limbago, J.K. Rasheed, K.F. Anderson et al. // Journal of Clinical Microbiology. – 2011. – Vol. 49, N 12. – P. 4239–4245.
Inhaled phage therapy: a promising and challenging approach to treat bacterial respiratory infections / E. Bodier Montagutelli, E. Morello, G. L’Hostis, et al. // Expert Opinion on Drug Delivery. – Nov 2016. – P. 1–14.
Kutter E.M. Bacteriophage therapy: past and present / E.M. Kutter // In: Encyclopedia of Microbiology. Ed.: M. Schaecter. – Oxford: Elsevier, 2009. – P. 258–266.
Literature Review of the Practical Application of Bacteriophage Research / Eds.: N. Chanishvili, R.A. Sharp – Tbilisi, Georgia: Eliava Institute, 2009. – 184 p.
Mann N.H. The potential of phages to prevent MRSA infections / N.H. Mann // Res Microbiol. – 2008. – Vol. 159. – P. 400–405.
Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe / R. Köck, K. Becker, B. Cookson et al. // Euro Surveill. – 2010. – Vol. 15, N 41. – P. 19688.
New Delhi metallo-β-lactamase around the world: an eReview using Google Maps / M. Berrazeg, S. Diene, L. Medjahed, et al. // Euro Surveill. – 2014. – Vol. 19, N 20. – pii.20809.
Non prescription antimicrobial use worldwide: a systematic review / D.J. Morgan, I.N. Okeke, R. Laxminarayan, et al. // Lancet Infect Dis. – 2011. – Vol. 11, N 9. – P. 692–701.
Oral application of Escherichia coli bacteriophage: safety tests in healthy and diarrheal children from Bangladesh / S.A. Sarker, B. Berger, Y. Deng, S. Kieser, et al. // Environ Microbiol. – 2017. – Vol. 19, N 1. – P. 237–250.
Phage Host interaction: an ecological perspective / S. Chibani Chennoufi, A. Bruttin, M. L. Dillmann, H. Brüssow // J. Bacteriol. – 2004. – Vol. 186, N 12. – P. 3677–3686.
Phage therapy in clinical practice: treatment of human infections / E. Kutter, D. De Vos, G. Gvasalia, et al. // Curr Pharm Biotechnol. – 2010. – Vol. 11. – P. 69–86.
Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa / E.M. Waters, D.R. Neill, B. Kaman, et al // Thorax. – 2017. – Vol. 72. – P. 666–667.
Phage treatment of human infections / S.T. Abedon, S.J. Kuhl, B.G. Blasdel, E.M. Kutter // Bacteriophage. – 2011. – Vol. 1, N 2. – P. 66–85.
Potential of the polyvalent anti Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals / S. O’Flaherty, R.P. Ross, W. Meaney, et al. // Appl Environ Microbiol. – 2005. – Vol. 71. – P. 1836–1842.
Pray L. Antibiotic resistance, mutation rates and MRSA / L. Pray // Nature Educ. – 2008. – Vol. 1, N 1. – P. 30.
Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits 2010–2011 / K.E. Fleming Dutra, A.L. Hersh, D.J. Shapiro et al. // JAMA. – 2016. – Vol. 315, N 17. – P. 1864–1873.
Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986 / S. Slopek, B. Weber Dabrowska, M. Dabrowski, A. Kucharewicz Krukowska // Arch Immunol Ther Exp (Warsz). – 1987. – Vol. 35. – P. 569–583.
Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results / Slopek S, Durlakova I, Weber Dabrowska B, et al. // Arch Immunol Ther Exp (Warsz). – 1983. – Vol. 31. – P. 267–291.
Results of bacteriophage treatment of suppurative bacterial infections. II. Detailed evalulation of the results / S. Slopek, I. Durlakova, B. Weber Dabrowska, et al. // Arch Immunol Ther Exp (Warsz). – 1983. – Vol. 31. – P. 293–327.
Results of bacteriophage treatment of suppurative bacterial infections. III. Detailed evaluation of the results obtained in further 150 cases / S. Slopek, I. Durlakova, B. Weber Dabrowska, et al. // Arch Immunol Ther Exp (Warsz). – 1984. – Vol. 32. – P. 317–335.
Results of bacteriophage treatment of suppurative bacterial infections. IV. Evaluation of results obtained in 370 cases / S. Slopek, A. Kucharewicz Krukowska, B. Weber Dabrowska, M. Dabrowski // Arch Immunol Ther Exp (Warsz). – 1985. – Vol. 33. – P. 219–240.
Results of bacteriophage treatment of suppurative bacterial infections. V. Evaluation of the results obtained in children / S. Slopek, A. Kucharewicz Krukowska, B. Weber Dabrowska, M. Dabrowski // Arch Immunol Ther Exp (Warsz). – 1985. – Vol. 33. – P. 241–259.
Results of bacteriophagetreatment of suppurative bacterial infections.VI. Analysis of treatment of suppurative staphylococcal infections / S. Slopek, A. Kucharewicz Krukowska, B. Weber Dabrowska, M. Dabrowski // Arch Immunol Ther Exp (Warsz). – 1985. – Vol. 33. – P. 261–273.
Salmond G.P.C. A century of the phage: past, present and future / G.P.C. Salmond, P.C. Fineran // Nature Reviews Microbiology. – 2015. – Vol. 13. – P. 777–786.
Strydom A. Listeria monocytogenes: A Target for Bacteriophage Biocontrol / A. Strydom, C.R. Witthuhn // Comprehensive Reviews in Food Science and Food Safety. – 2015. – Vol. 14, N 6. – P. 694–704.
Sulakvelidze A. Bacteriophage ther apy in humans / A. Sulakvelidze, E. Kutter // In: Bacteriophages: Biology and Application. Eds.: E. Kutter, A. Sulakvelidze. – Boca Raton, FL: CRC Press, 2005. – P. 381–436.
Summers W.C. Cholera and plague in India: the bacteriophage inquiry of 1927 1936 / W.C. Summers // J Hist Med Allied Sci. – 1993. – Vol.48, N3. – P. 275-301.
Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: A before/after clinical trial / C. Hawkins, D. Harper, D. Burch, et al.// Vet Microbiol. – 2010. – Vol. 146. – P. 309–313.
The Review on Antimicrobial Resistance. Tackling drug resistant infections globally: final report and recommendations [Електронний ресурс] / Ed: Jim O’Neill // UK Government and Wellcome Trust, 2016. Режим доступу: https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf
US Food and Drug Administration. 2014Summary report on antimicrobials sold or distributed for use in food producing animals [Електронний ресурс] / Food and Drug Administration Department of Health and Human Services, December, 2015. Режим доступу: http://www.fda.gov/downloads/ForIndustry/UserFees/AnimalDrugUserFeeActADUFA/UCM476258.pdf
Waste water effluent contributes to the dissemination of CTX-M-15 in the
natural environment / G.C.A. Amos, P.M. Hawkey, W.H. Gaze, E.M. Wellington // Journal of Antimicrobial Chemotherapy. – 2014. – Vol. 69. – P. 1785–1791.
Weber Dabrowska B. Bacteriophage therapy of bacterial infections: an update of our institute’s experience / B. Weber Dabrowska, M. Mulczyk, A. Górski // Arch Immunol Ther Exp (Warsz). – 2000. – Vol. 48. – P. 547–551.
